Current Neuro-Oncology

Volume 27 Number 23
20 August 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 23, 20 August

van Hout L, Borgo AD, Grun N, Schuur M, Broen MPG, Westerman BA, Bartelink I, Vandertop WP, Lissenberg-Witte BI, Kouwenhoven MCM.
Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionally impacts female patients.
Neurooncol Pract. 2025 Jan 22;12(4):678-690. doi: 10.1093/nop/npaf013. PMID: 40814424. Observational study. ˍ

Affronti ML, Patel MP, Severance EK, Loughlin C, Bradbury C, Herndon JE, Boyd K, Lipp ES, Friedman HS, Desjardins A, Johnson MO, Peters KB.
Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting.
Neurooncol Pract. 2025 Jan 28;12(4):618-630. doi: 10.1093/nop/npaf014. PMID: 40814434. Interventional study˰ Meeting abstract. ˍ

Brown NF, McBain C, Brazil L, Peoples S, Jefferies S, Harris F, Vinayan A, Plaha P, Brooks C, Hussain S, Dutton SJ, Cook J, Ng SM, Levy S, Coutts T, Mulholland P.
Ipilimumab with temozolomide vs. temozolomide alone after surgery and chemoradiotherapy in recently diagnosed glioblastoma: a randomized phase II clinical trial.
Neurooncol Adv. 2025 May 26;7(1):vdaf032. doi: 10.1093/noajnl/vdaf032. PMID: 40800123. Interventional study. ˍ ISRCTN.com ID: ISRCTN84434175.

Youssef M, Larson A, Udhane V, Schilter KF, Nie Q, Reddi HV.
Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adult.
J Liq Biopsy. 2025 Jul 25;9:100318. doi: 10.1016/j.jlb.2025.100318. PMID: 40792228. Case report. ˍ

Zou M, Guo X, Xie W, Jiang J, Li W, Kang X.
Identification of Malignant Progression of Gliomas through Metabolomics of Cerebrospinal Fluid and Serum.
ACS Omega. 2025 Aug 2;10(31):34190-34203. doi: 10.1021/acsomega.5c00296. PMID: 40821575. Translational study. ˍ

Genc O, Tabakci ON, Uysal E, Şahin SA, Tanık CT.
The Diagnostic Value of Susceptibility-Weighted Imaging in Preoperative Grading of Glial Tumors.
Cureus. 2025 Aug 10;17(8):e89757. doi: 10.7759/cureus.89757. PMID: 40791217. Observational study. ˍ

Glioblastoma; Oligodendroglioma

Blumenfeld P, Pryanichnikov A, Hillman Y, Wajnryt E, Berger A, Winograd S, Wygoda M, Salhab A, Fang M, Feldman J, Popovtzer A.
Prospective clinical trial of upright image-guided proton therapy for locally recurrent head and neck and brain malignancies.
Radiother Oncol. 2025 Aug 11;211:111097. doi: 10.1016/j.radonc.2025.111097. PMID: 40803484. Interventional study. ˍ

Li HY, Lao IH, Chen YC, Wu YY, Chu YC, Wei KC, Chen PY, Yeh CC, Chen WC, Chang WH, Chang HT, Chen KT.
Impact of Subventricular Zone Invasion on Preoperative Cognitive Decline in Patients with Diffuse Glioma.
Neurosurgery. 2025 Aug 11. doi: 10.1227/neu.0000000000003676. PMID: 40788002. Observational study. ˍ

Depond CC, Jecko V, Weller J, Tuppin P, Metellus P.
Overall survival after carmustine wafers implantation for newly-diagnosed high grade glioma. A nationwide population-based controlled propensity score-matched analysis.
Clin Neurol Neurosurg. 2025 Aug 12;257:109081. doi: 10.1016/j.clineuro.2025.109081. PMID: 40848613. Observational study˰ ˍ

Tang H, Dai Q, Zhao Z, Ge W, Li D, Chang Z, Pi P, Li J, Sun Z.
Melatonin Synergises the Chemotherapeutic Effect of Temozolomide in Glioblastoma by Suppressing NF-κB/COX-2 Signalling Pathways.
J Cell Mol Med. 2025 Aug 13;29(15):e70778. doi: 10.1111/jcmm.70778. PMID: 40804775. Lab investigation. ˍ

Rha SY, Castanon E, Gill S, Senellart H, Lopez J, Márquez-Rodas I, Victoria I, Kim TM, Lwin Z, Burger MC, Simonelli M, Cassier PA, Hendifar AE, Ascierto PA, Dutcus C, Okpara CE, Ghori R, Jin F, Groisberg R, Villanueva L.
Lenvatinib plus pembrolizumab for patients with previously treated select solid tumors: Results from the phase 2 LEAP-005 study recurrent glioblastoma cohort.
Cancer. 2025 Aug 15;131(16):e70015. doi: 10.1002/cncr.70015. PMID: 40808295. Interventional study. ˍ ClinicalTrials.gov ID: NCT03797326.

Taiwo R, Harary PM, Trinh TTH, Granucci M, Bertrand S, Carlson-Clarke B, Chernikova SB, Therkelsen K, Arora M, Melisko ME, Iv M, Vogel H, Han S, Xie C, Brain S, Lee V, Bharani KL, Nagpal S, Hayden Gephart M.
Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
BMC Cancer. 2025 Aug 15;25(1):1316. doi: 10.1186/s12885-025-14282-x. PMID: 40813655. Interventional study protocol. ˍ ClinicalTrials.gov ID: NCT05305365.

Barish ME, Aftabizadeh M, Hibbard J, Blanchard MS, Ostberg JR, Wagner JR, Manchanda M, Paul J, Stiller T, Aguilar B, Starr R, Arvanitis L, Ressler JA, Kilpatrick J, Kong Y, Wang D, Forman SJ, D'Apuzzo M, Brown CE, Badie B.
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety.
Cell Rep Med. 2025 Aug 15;6(8):102302. doi: 10.1016/j.xcrm.2025.102302. PMID: 40818458. Interventional study. ˍ ClinicalTrrials.gov ID: NCT04214392.

Jacobsen J, Locallo A, O'Rourke CJ, Carlsen JF, Cohen J, Ewald JD, Scheie D, Grunnet K, Schmidt AY, Melchior LC, Larsen VA, Andersen JB, Poulsen HS, Weischenfeldt J, Broholm H, Michaelsen SR, Kristensen BW.
Clinical, Radiological, and Molecular Insights into Extracranial Metastases from Adult Gliomas.
Neuro Oncol. 2025 Aug 16:noaf178. doi: 10.1093/neuonc/noaf178. PMID: 40842361. Observational study. ˍ

Gry HS, Falk Delgado A.
Differentiation of Molecular Glioblastomas and Lower-grade Diffuse Astrocytomas Using MRI Perfusion and Diffusion Parameters.
Clin Neuroradiol. 2025 Aug 20. doi: 10.1007/s00062-025-01550-3. PMID: 40833458. Observational study˰ ˍ

Yogendran LV, Kareddy A, Abbas SO, Scharf Z, Patrie J, Patel SH, Schiff D.
Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.
J Neurooncol. 2025 Aug 20. doi: 10.1007/s11060-025-05087-w. PMID: 40836201. Observational study. ˍ